论文部分内容阅读
２０例急性心肌梗死患者在溶栓后随机分为穿心莲有效成分（ＡＰＩ０１３４，ＡＰＩ）组与对照组，治疗１５ｄ，均同时给予阿司匹林等药物。检测溶栓前后血浆α颗粒膜蛋白（ＧＭＰ－１４０）浓度和ＡＤＰ诱导的血小板聚集反应。结果表明，ＡＰＩ组溶栓后７２ｈ血浆ＧＭＰ－１４０浓度轻度增加，对照组显著性增加（Ｐ＜０．０１）。ＡＰＩ组ＧＭＰ－１４０在溶栓后７２ｈ和１５ｄ均低于对照组，差异有显著意义（均为Ｐ＜０．０５）。ＡＰＩ组１ｍｉｎ和５ｍｉｎ血小板聚集率均低于对照组，差异均有显著意义（７２ｈ，Ｐ＜０．０５；１５ｄ，Ｐ＜０．０１）。研究表明，ＡＰＩ与阿司匹林联合应用可抑制溶栓后血小板的活化，优于阿司匹林单独应用，因此ＡＰＩ有可能用于临床预防溶栓后的再闭塞。
Twenty patients with acute myocardial infarction were randomly divided into the active ingredients (API0134, API) group and the control group after thrombolysis. After 15 days of treatment, aspirin and other drugs were given at the same time. The concentration of plasma GMP-140 and the platelet aggregation induced by ADP were measured before and after thrombolysis. The results showed that the concentration of plasma GMP-140 increased slightly in the API group 72 hours after thrombolysis and increased significantly in the control group (P<0.01). GMP-140 in the API group was lower than the control group 72h and 15d after thrombolysis, and the difference was significant (all P<0.05). Platelet aggregation rate in API group was lower than that in control group at 1min and 5min, and the difference was significant (72h, P<0.05; 15d, P<0.01). Studies have shown that the combination of API and aspirin can inhibit the activation of platelets after thrombolysis, superior to aspirin alone, so the API may be used to clinically prevent reocclusion after thrombolysis.